These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 14760067)

  • 21. Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors.
    Mita AC; Denis LJ; Rowinsky EK; Debono JS; Goetz AD; Ochoa L; Forouzesh B; Beeram M; Patnaik A; Molpus K; Semiond D; Besenval M; Tolcher AW
    Clin Cancer Res; 2009 Jan; 15(2):723-30. PubMed ID: 19147780
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cytotoxic alpha-halogenoacrylic derivatives of distamycin A and congeners.
    Beria I; Baraldi PG; Cozzi P; Caldarelli M; Geroni C; Marchini S; Mongelli N; Romagnoli R
    J Med Chem; 2004 May; 47(10):2611-23. PubMed ID: 15115402
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase I and pharmacokinetic study of tallimustine [PNU 152241 (FCE 24517)] in patients with advanced cancer.
    Weiss GR; Poggesi I; Rocchetti M; DeMaria D; Mooneyham T; Reilly D; Vitek LV; Whaley F; Patricia E; Von Hoff DD; O'Dwyer P
    Clin Cancer Res; 1998 Jan; 4(1):53-9. PubMed ID: 9516952
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Zebularine partially reverses GST methylation in prostate cancer cells and restores sensitivity to the DNA minor groove binder brostallicin.
    Sabatino MA; Geroni C; Ganzinelli M; Ceruti R; Broggini M
    Epigenetics; 2013 Jun; 8(6):656-65. PubMed ID: 23771052
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase I and pharmacokinetic study of the novel aza-anthracenedione compound BBR 2778 in patients with advanced solid malignancies.
    Faivre S; Raymond E; Boige V; Gatineau M; Buthaut X; Rixe O; Bernareggi A; Camboni G; Armand JP
    Clin Cancer Res; 2001 Jan; 7(1):43-50. PubMed ID: 11205916
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase 1 study of weekly polyethylene glycol-camptothecin in patients with advanced solid tumors and lymphomas.
    Posey JA; Saif MW; Carlisle R; Goetz A; Rizzo J; Stevenson S; Rudoltz MS; Kwiatek J; Simmons P; Rowinsky EK; Takimoto CH; Tolcher AW
    Clin Cancer Res; 2005 Nov; 11(21):7866-71. PubMed ID: 16278410
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phase I study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously daily for 5 consecutive days every 3 weeks in patients with advanced solid tumors.
    Ebbinghaus S; Rubin E; Hersh E; Cranmer LD; Bonate PL; Fram RJ; Jekunen A; Weitman S; Hammond LA
    Clin Cancer Res; 2005 Nov; 11(21):7807-16. PubMed ID: 16278403
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I clinical and pharmacokinetic study of kahalalide F administered weekly as a 1-hour infusion to patients with advanced solid tumors.
    Pardo B; Paz-Ares L; Tabernero J; Ciruelos E; García M; Salazar R; López A; Blanco M; Nieto A; Jimeno J; Izquierdo MA; Trigo JM
    Clin Cancer Res; 2008 Feb; 14(4):1116-23. PubMed ID: 18281545
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 given as a 1-hour intravenous infusion in patients with advanced solid tumors.
    Ryan DP; Eder JP; Puchlaski T; Seiden MV; Lynch TJ; Fuchs CS; Amrein PC; Sonnichsen D; Supko JG; Clark JW
    Clin Cancer Res; 2004 Apr; 10(7):2222-30. PubMed ID: 15073096
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
    Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
    Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I and pharmacokinetic study of irofulven administered weekly or biweekly in advanced solid tumor patients.
    Alexandre J; Raymond E; Kaci MO; Brain EC; Lokiec F; Kahatt C; Faivre S; Yovine A; Goldwasser F; Smith SL; MacDonald JR; Misset JL; Cvitkovic E
    Clin Cancer Res; 2004 May; 10(10):3377-85. PubMed ID: 15161692
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase I and pharmacologic study of PKI166, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies.
    Hoekstra R; Dumez H; Eskens FA; van der Gaast A; Planting AS; de Heus G; Sizer KC; Ravera C; Vaidyanathan S; Bucana C; Fidler IJ; van Oosterom AT; Verweij J
    Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6908-15. PubMed ID: 16203782
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase I and pharmacokinetic study of 1843U89, a noncompetitive inhibitor of thymidylate synthase, in patients with advanced solid malignancies.
    Schwartz G; Johnson TR; Goetz A; Burris H; Smetzer L; Lampkin T; Sailstad J; Hohneker JA; Von Hoff DD; Rowinsky EK
    Clin Cancer Res; 2001 Jul; 7(7):1901-11. PubMed ID: 11448903
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation.
    Rinaldi DA; Kuhn JG; Burris HA; Dorr FA; Rodriguez G; Eckhardt SG; Jones S; Woodworth JR; Baker S; Langley C; Mascorro D; Abrahams T; Von Hoff DD
    Cancer Chemother Pharmacol; 1999; 44(5):372-80. PubMed ID: 10501910
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase I clinical and pharmacokinetic study of BBR 3576, a novel aza-anthrapyrazole, administered i.v. every 4 weeks in patients with advanced solid tumors: a phase I study group trial of the Central European Society of Anticancer-Drug Research (CESAR).
    Mross K; Scheulen ME; Licht T; Unger C; Richly H; Stern AC; Kutz K; Camboni MG; Barbieri P; Verdi E; Vincenzi B; Bernareggi A
    Anticancer Drugs; 2004 Jan; 15(1):15-22. PubMed ID: 15090738
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase I study of cantuzumab mertansine administered as a single intravenous infusion once weekly in patients with advanced solid tumors.
    Helft PR; Schilsky RL; Hoke FJ; Williams D; Kindler HL; Sprague E; DeWitte M; Martino HK; Erickson J; Pandite L; Russo M; Lambert JM; Howard M; Ratain MJ
    Clin Cancer Res; 2004 Jul; 10(13):4363-8. PubMed ID: 15240523
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I clinical and pharmacokinetic study of titanocene dichloride in adults with advanced solid tumors.
    Korfel A; Scheulen ME; Schmoll HJ; Gründel O; Harstrick A; Knoche M; Fels LM; Skorzec M; Bach F; Baumgart J; Sass G; Seeber S; Thiel E; Berdel WE
    Clin Cancer Res; 1998 Nov; 4(11):2701-8. PubMed ID: 9829732
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase I dose escalation study of TTI-237 in patients with advanced malignant solid tumors.
    Wang-Gillam A; Arnold SM; Bukowski RM; Rothenberg ML; Cooper W; Wang KK; Gauthier E; Lockhart AC
    Invest New Drugs; 2012 Feb; 30(1):266-72. PubMed ID: 20697774
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase I and pharmacokinetic study of edotecarin, a novel topoisomerase I inhibitor, administered once every 3 weeks in patients with solid tumors.
    Yamada Y; Tamura T; Yamamoto N; Shimoyama T; Ueda Y; Murakami H; Kusaba H; Kamiya Y; Saka H; Tanigawara Y; McGovren JP; Natsumeda Y
    Cancer Chemother Pharmacol; 2006 Aug; 58(2):173-82. PubMed ID: 16308697
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I dose-escalation study of a novel antitumor agent, SR271425, administered intravenously in split doses (d1-d2-d3) in patients with refractory solid tumors.
    Campone M; Isambert N; Bourbouloux E; Maury S; Monin-Baroille P; Berille J; Fumoleau P
    Cancer Chemother Pharmacol; 2007 Apr; 59(5):689-95. PubMed ID: 17031647
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.